Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say

Executive Summary

It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience

You may also be interested in...



AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?

Antiplatelet ticagrelor will likely confront the "North American anomaly" during its July 28 review by FDA's cardio-renal panel.

A Return Of The Blockbuster, But Can 2009 Launches Live Up To Potential?

The blockbuster drug tried to claw its way back from the brink in 2009, as drug makers launched several novel drugs and biologics in multi-billion dollar therapeutic categories. While several new drugs offer blockbuster potential, they raise two questions: will they live up to their promise, and if so, how long will it take

A Return Of The Blockbuster, But Can 2009 Launches Live Up To Potential?

The blockbuster drug tried to claw its way back from the brink in 2009, as drug makers launched several novel drugs and biologics in multi-billion dollar therapeutic categories. While several new drugs offer blockbuster potential, they raise two questions: will they live up to their promise, and if so, how long will it take

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel